Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: Prognostic significance

Laboratory Hematology

Volumn 13, Issue 1, 2007, Pages 22-26

  Ruiz Argüelles, Guillermo J ^a,b   Fernández Lara, Danitza ^a,c   Estrada Gómez, Robert ^b   Manzano, Carlos ^a   Ruiz Delgado, Guillermo J ^d   Pérez Romano, Beatriz ^b   Ruiz Argüelles, Alejandro ^b  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c Hospital Angeles de Interlomas   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Acute leukemia; Flow cytometry; Follow up; Minimal residue disease

Indexed keywords

ANTHRACYCLINE; CYTARABINE; RETINOIC ACID;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PROGNOSIS; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FLOW CYTOMETRY; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS;

EID: 34147214155     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.06045     Document Type: Article

References (22)

1. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995:85:1416-1434.
2. San-Miguel JF, Orfao A, Ruiz-Argüelles A. Identificadón y vigilancia de enfermedad residual mínima en leucemia aguda. In: Ruiz-Argüelles GJ, San-Miguel JF, eds. Actualización en Leucemias. Editorial Médica Panamericana. Ciudad de México, México; 1996:147-151.
3. Ruiz-Argüelles GJ, Garcés-Eiselc J, Reyes-Núñez V, et al. Assessment of residual disease in acute leukemia by means of polymerase chain reaction: a prospective study in a single institution. Rev Invest Clin. 2000;52-118-124.
4. Ruiz-Argüelles GJ, McArthur JR. Leucemias agudas. In: Ruiz-Argüelles GJ, ed. Fundamentos de Hematologia. 3a ed. AMEH. Editorial Médica Panamericana, México; 2003:225-245.
5. Rivera GK, Raimondi SC, Hancock MI, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61-66.
6. Ruiz-Argüelles GJ, Apreza-Molina MG. Resultados del tratamiento de las leucemias agudas en adolescentes. Rev Invest Clin. 1997;49:271-275.
7. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. Eur J Haematol. 1995;54:.18-20.
8. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A. Molecular follow-up of patients with promyelocytic leukaemia treated with all trans-retinoic acid. Clin Lab Haematol. 1998;20:173-176.
9. Ruiz-Argüelles A, Duque RE, Orfao A. Report on the first Latin American Consensus Conference for Flow Cytomettic Immunophenotyping of Leukemia. Cytometry. 1998;34:39-42.
10. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American Consensus Conference for Flow Cytometric Immunophenotyping of Hematological Malignancies. Cytometry B Clin Cytom. 2006;70:39-44.
11. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochem. 1987;162:156-159.
12. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, A Laboratory Manual. 2nd ed. Cold Spring Laboratory Press, New York, NY, 1989.
13. Deane M, Norton JD. Immunoglobulin gene fingerprinting. An approach to analysis of B lymphoid clonality in lymhpoproliferative disorders. Br J Haematol. 1991;77:274-281.
14. Height SE, Swansbury GJ, Matutes E, Treleaven E, Catovsky D, Dyer MJ. Analysis of clonal rearrangements of the Ig heavy chain locus in acute leukemia. Blood. 1996;87:5242-5250.
15. Reyes-Núñiez V, Ruiz-Argüelles A, Ruiz-Argüelles GJ, Garcés-Eisele J. Improved molecular detection of minimal residual disease in lymphoid neoplasms. In: Abstracts of the International Symposium on Minimal Residual Disease. Salamanca, Spain; 1997:88.
16. Reyes-Núñez V. Molecular Detection of Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia. [Masters thesis]. Puebla, Mexico: Universidad de las Américas; 1998.
17. Biondi A, Rambaldi A, Pandolfi PP et al. Molecular monitoring of the myl/ retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood. 1992;80:492-497.
18. Kozu T, Miyoshi H, Shimizu K, et al. junctions of the AMLI/MTG8 (ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood. 1993;82:1270-1276.
19. Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert E Incidence of TEL/ AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
20. Claxton DF, Liu P, Hsu HB, et al. Detection of fitsion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83:1750-1756.
21. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-463.
22. Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399-2402.